Table 1.

Baseline data for patients with T2DM using 1:5 matching with propensity score for each comparison

	Metformin versus SU					Metformin versus meglitinide
	Metformin	SU	Mean difference	Standardized difference	p Value	Metformin	Meglitinide	Mean difference	Standardized difference	p Value
Number	3585	717				1090	218
Propensity score	0.106±0.081	0.105±0.079	0.001	0.01	0.8	0.0431±0.041	0.0439±0.041	−0.0008	−0.02	0.8
Age	71.02±8.9	71.01±10.4	0.01	0.01	0.9	71.5±8.9	71.4±10.4	0.1	0.01	0.9
Diabetes duration	4.4±4.1	4.6±3.8	−0.2	0.03	0.4	5.0±5.1	4.9±4.5	0.1	0.03	0.7
HbA1c	56.0±12.2	55.8±10.2	0.2	0.02	0.7	55.9±11.9	56.2±12.2	−0.3	−0.02	0.8
BMI	27.9±3.5	27.9±4.3	0.0	0.01	0.9	27.5±3.8	27.3±4.7	0.2	0.04	0.5
eGFR	77.6±17.4	78.0±23.6	−0.4	−0.02	0.6	76.9±18.0	77.5±23.6	−0.6	0.03	0.7
Male gender	59.8	59.3	0.5	−0.01	0.8	68.3	68.4	−0.1	0.01	0.9
Previous CVD	15.9	19.4	3.5	−0.09	0.03	16.5	15.1	1.4	0.04	0.6
Previous CHF	4.3	4.7	−0.4	−0.02	0.6	6.1	6.4	−0.3	−0.02	0.8
Atrial fibrillation	7.7	7.3	0.4	0.02	0.7	9.3	11.0	−1.7	−0.06	0.4
Education score 1–3	1.72±0.72	1.75±0.73	−0.03	−0.04	0.3	1.72±0.72	1.71±0.77	0.01	0.01	0.7
Psychiatric drugs	20.5	22.0	−1.5	−0.04	0.4	19.8	22.9	−3.1	−0.08	0.3
Multidose	1.1	1.8	−0.7	−0.06	0.11	1.0	0.5	0.5	0.06	0.4
Start year, mean	2008.2±1.3	2008.2±1.3	0.0	0.02	0.6	2007.8±1.3	2007.8±1.2	0.0	−0.021	0.9

Data given as means±SD or frequencies (%).

Standardized difference: for continuous variables (means and SDs estimated as customary): (mean A—mean B)/sqrt ((SD_A²+SD_B²)/2; for categorical variables: (freq A—freq B)/sqrt ((freq A * [1-freq A])+(freq B * [1-freq B]))/2.

BMI, body mass index; CHF, congestive heart failure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; multidose: multidose drug dispensing; SU, sulfonylurea; T2DM, type 2 diabetes mellitus.